Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA - Wikidata - awgldk - TriplyDB

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

http://www.wikidata.org/entity/Q35810461

about

Circulating tumor DNA in hepatocellular carcinoma: trends and challenges Cell-free circulating tumor DNA in cancer Technological considerations for genome-guided diagnosis and management of cancer Clinical applications of liquid biopsies in gastrointestinal oncology Targeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and Treatment Implementing Genome-Driven Oncology.Liquid biopsy genotyping in lung cancer: ready for clinical utility?Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA Cell-free DNA from human plasma and serum differs in content of telomeric sequences and its ability to promote immune response.Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes.Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery.Liquid Biopsies for Cancer: Coming to a Patient near You.The Pursuit of Noninvasive Diagnosis of Lung Cancer.Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution.Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma.Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.Tumor evolution: Linear, branching, neutral or punctuated?Liquid biopsies come of age: towards implementation of circulating tumour DNA.Integrating liquid biopsies into the management of cancer.Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.Current status of research and treatment for non-small cell lung cancer in never-smoking females.Platelets, circulating tumor cells, and the circulome.Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature Clinical utility of circulating cell-free DNA in advanced colorectal cancer.MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon.Cons: Can liquid biopsy replace tissue biopsy?-the US experience.Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative.MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.

P2860

Q26749417-E07636EC-985B-426B-9646-EB952FF60FA0 Q26750899-561B2E88-E478-463F-809B-985D2B12929F Q28066706-BD668352-D283-4D4E-8E91-91A8B9D025EE Q28073730-78048076-62FA-47FD-99C6-AE34A7ADDD0C Q28076462-7F251DCD-EC28-41D3-B6C8-68C2110B41D4 Q30235979-A2EBF2AF-1E41-44D9-94FD-828244AEBCB3 Q33567037-98A38C07-0CEC-4547-BDFB-703474B5489E Q33640472-57A77467-BCB8-4707-BDCF-9E98DC2797D4 Q33673752-0CFF815E-B93A-4879-8656-792C108F43DC Q33737740-2B936C34-D90D-4AE5-BA2D-CCB90EABDBCE Q33752880-4A9E5DD2-53F9-4BF8-99DD-9D7F9D72EB4D Q33779585-38DA84AC-DD35-4711-B90B-604DBF1D9937 Q36716660-CA53DF6B-5B2A-4B81-BB97-0C9299982FAD Q37529593-951BEB11-F853-4599-B618-6309AEFD5500 Q37593245-2B35FE91-02B5-41DE-8425-5D1087196244 Q37628173-EE2D272B-6E80-4A77-989F-73819F57CF35 Q37652904-1A5FC894-181F-463B-BF5B-5E92B86F569E Q37687088-436B8080-24B7-4FD4-9C54-EEAFBBCF9651 Q37690677-A4C75FC6-09B7-443D-80EE-AEB016EDA6AE Q37695228-1B742C3D-4C8A-4D28-8175-312C28C1B1DD Q38405569-70469D51-34E1-4BBB-B3ED-AA941DBBFD5E Q38669236-4538218D-2317-4B01-8760-35853A3D582B Q38679628-80AC8D12-6C8C-4A2E-BC5A-741C36115749 Q38700529-04B6FBDB-4085-44AB-A6DB-8499E60EBD6C Q38776411-DE0DCEF4-EED7-4629-8EE5-86A0F4823CDE Q38966736-37383F55-3C94-4C78-98AD-3625B4EB73D1 Q39007635-FFB1F482-07A9-4E2A-B0E8-C25EA3859D43 Q39149201-715F9C52-D6BB-47C4-9FC3-00027A67FFC2 Q39157824-016A53A2-9A76-4598-9ECE-A036F18AC957 Q39244943-77EA936A-E0B7-4550-B355-68130FBB4635 Q39298725-73FAABE2-AB30-4DB7-99D9-6914C5EA2537 Q39408199-0B0F8B39-9418-4D14-940C-E28F7BF3630A Q40203060-DC3ED896-07C9-4B5B-B8E1-F2A7C6CFA8A7 Q41339309-584FD708-F3DA-470B-A11C-63F420891585 Q41545171-FA525600-BDC0-481C-B7D1-2EBE6ABC8AD4 Q42317509-DC4158E5-953F-4B8E-A90C-D40C67AB814E Q42398713-FD2087D1-6820-4276-B8E1-617E3D24DEF7 Q43045850-D4C1D162-33FD-472E-B7FC-1FE04F9BF543 Q43763245-22DE7FB6-1EB7-4260-AC1C-B1F074168CFC Q44820646-F9935EA5-5B61-412D-9A87-06D607CC54F3

P2860

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

http://www.wikidata.org/entity/Q35810461

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Analytical and Clinical Valida ...... ell-Free Circulating Tumor DNA

@ast

Analytical and Clinical Valida ...... ell-Free Circulating Tumor DNA

@en

type

label

Analytical and Clinical Valida ...... ell-Free Circulating Tumor DNA

@ast

Analytical and Clinical Valida ...... ell-Free Circulating Tumor DNA

@en

prefLabel

Analytical and Clinical Valida ...... ell-Free Circulating Tumor DNA

@ast

Analytical and Clinical Valida ...... ell-Free Circulating Tumor DNA

@en

P1433

Q35810461-B80C771D-54E9-4E52-9EDD-21A506A4551F

P1476

Q35810461-DB8A67D9-C7EA-41B6-96E2-E12239532EAD

P2093

Q35810461-000DB956-B2EA-49AB-BD5E-C4226FBA3965

Q35810461-273C0372-AE27-4416-B8E6-E8315029DB34

Q35810461-3A134493-BB6D-4751-92EE-193DD880CAB8

Q35810461-3E598F25-A5DC-4E05-9A3E-BC168F9B4EDF

Q35810461-5AF9D384-CD56-4A73-AD28-97B4EE0B2C02

Q35810461-5E38E6C3-97BA-46E9-808D-393FD6E45CDA

Q35810461-866807CE-5C53-444C-B710-227DAAE2A1E9

Q35810461-8FC0B9EF-666E-4C06-BBE4-732FDB8AD3B3

Q35810461-A69A4D11-AFA0-4220-9484-84E0CF54E657

Q35810461-B564ECD0-17E6-4CB1-9DE1-043EAC01D031

P2860

Q35810461-0AD69956-6468-461F-800C-3B73EEF6D1B4

Q35810461-0BD797BC-CA4F-4359-8845-3295D581130A

Q35810461-11710D2E-6392-41FA-A4DE-6E771A9301EC

Q35810461-19262FF9-947B-43B5-A50F-82F2A293DB68

Q35810461-19FEEE14-6D07-4455-894C-C35FBF698DDF

Q35810461-1B93E6A5-1F75-49B8-9CE9-2450DC8AAFE6

Q35810461-1CBA71D1-3962-408A-9534-543BBC8AADFF

Q35810461-203DBC81-AF96-4893-AFED-493C6A240254

Q35810461-21643F59-61AE-486C-A0B8-1697D1EB3180

Q35810461-2A0571CD-E283-4900-960C-3631D745EFAC

P304

Q35810461-16A2F2C6-2C8F-4472-B805-0B649BBB758C

P31

Q35810461-C9A2A455-0F44-4F55-B025-DEAD583F9A0F

P356

Q35810461-08F1027E-3355-4374-8C3A-E1C84B827EBF

P407

Q35810461-FA6511ED-9653-49F8-8B3A-047A815F84D9

P433

Q35810461-193054DF-3ABF-4F01-BA0D-0C3F4E80E1B2

P478

Q35810461-6859E3E1-816A-42B0-91F0-6BC0F0BD5876

P50

Q35810461-360A6976-5BFF-42D1-99A5-D5CB437C3972

Q35810461-F56BE85B-FA71-4A23-A5F0-C7351604B959

P577

Q35810461-2DE77909-0C9B-4AC1-BF70-08184484A380

P5875

Q35810461-BF0999B2-1441-4861-819C-2C5E5D12CFDB

P698

Q35810461-CBD796F4-0B56-4131-A17D-140562323AF2

P932

Q35810461-D98EF03D-EA45-4045-902D-5FE81994B6EC

P356

JOURNAL.PONE.0140712

P1433

P1476

Analytical and Clinical Valida ...... ell-Free Circulating Tumor DNA

@en

P2093

AmirAli Talasaz

http://www.w3.org/2001/XMLSchema#string

Arthur M Baca

http://www.w3.org/2001/XMLSchema#string

Bahram G Kermani

http://www.w3.org/2001/XMLSchema#string

Dragan Sebisanovic

http://www.w3.org/2001/XMLSchema#string

Eric A Collisson

http://www.w3.org/2001/XMLSchema#string

Helmy Eltoukhy

http://www.w3.org/2001/XMLSchema#string

Jeeyun Lee

http://www.w3.org/2001/XMLSchema#string

Oliver A Zill

http://www.w3.org/2001/XMLSchema#string

Petros G Nikolinakos

http://www.w3.org/2001/XMLSchema#string

Rene Lopez

http://www.w3.org/2001/XMLSchema#string

P2860

Initial sequencing and analysis of the human genome

Intratumor heterogeneity: evolution through space and time

Accurate whole human genome sequencing using reversible terminator chemistry

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

Diagnostic tests. 1: Sensitivity and specificity

Liquid biopsies: genotyping circulating tumor DNA

Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation

P304

e0140712

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0140712

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282911754

http://www.w3.org/2001/XMLSchema#string

P698

26474073

http://www.w3.org/2001/XMLSchema#string

P932

4608804

http://www.w3.org/2001/XMLSchema#string